ARQT today
$28.38+$0.99 (+3.63%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minStrong Bullish
5 minExpanding
Daily trend turns down below $30.91
Key levels
Resistance$34.80
Resistance$30.91
Support$27.64
Support$25.23
Latest news & SEC filings
AnalystTD Cowen keeps Buy rating on Arcutis Biotherapeutics, lifts target to $40
NewsArcutis Biotherapeutics insider sells shares
All ARQT news →About Arcutis
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company that develops and sells topical treatments for immune-mediated skin conditions. Its main product line, ZORYVE, is a once-daily roflumilast-based cream and foam approved in the United States and Canada for several inflammatory skin disorders in adults and children. The company also develops ARQ-234, a biologic candidate for atopic dermatitis, and has licensing agreements covering topical roflumilast in parts of Asia.
Based on the company's 10-K filed Feb 25, 2026.
Nasdaq · Healthcare
Arcutis Biotherapeutics, Inc. (ARQT)
What Is the Price Target for ARQT?
SEPT Low Target
$36.00
SEPT Mid Target
$40.00
SEPT High Target
$48.00
Analyst Consensus
$40.00
Is ARQT a Buy or Sell Right Now?
Thesis
- •Revenue growing 91.3% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for ARQT.
Start Free Trial →Is ARQT Overvalued or Undervalued?
Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B, PEG, Analyst Consensus
Fair Value
$30.27
30
Moat Score
NONE
3/9
Piotroski Score
7.9
Altman Z-Score
What Is Smart Money Doing with ARQT?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
BUYING
1 buys / 1 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Matsuda Masaru | officer | Buy | 40,000 | $146K | Nov 4, 2026 |
| Matsuda Masaru | officer | Sale | 40,000 | $1.4M | Nov 4, 2026 |
| Burnett Patrick | officer | Sale | 943 | $30K | Nov 2, 2026 |
| Matsuda Masaru | officer | Sale | 1,219 | $39K | Nov 2, 2026 |
| Watanabe Todd | director officer | Sale | 4,377 | $139K | Nov 2, 2026 |
| SCOTT ROBERT A | director | Buy | 2,819 | - | Oct 23, 2026 |
| Matsuda Masaru | officer | Sale | 3,674 | $92K | Sep 16, 2026 |
| Matsuda Masaru | officer | Sale | 9,989 | $250K | Sep 8, 2026 |
| Curran Terrie | director | Buy | 11,148 | $84K | Aug 27, 2026 |
| Curran Terrie | director | Sale | 11,148 | $279K | Aug 27, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →ARQT Growth Story
Revenue YoY
91.3%
3yr Revenue CAGR
367.3%
EPS Growth YoY
88.79%
FCF Growth YoY
94.4%
Revenue Trend
STRONG
Dark Pool Trades for ARQT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for ARQT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:25:52 | $28.38 | 33,766 | $$958K | BUY |
| 21:57:56 | $28.38 | 158,499 | $$4.5M | BUY |
| 21:00:31 | $28.38 | 1,269 | $$36K | BUY |
| 21:00:31 | $28.38 | 2,316 | $$66K | BUY |
| 21:00:31 | $28.38 | 6,886 | $$195K | BUY |
5 dark pool trades shown · $$5.8M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for ARQT
PREVIEWSEPT Investing provides real-time options flow tracking for ARQT, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| PUT | $25 | Dec 18 | 37 | $$70 | 1 | SWEEP |
| PUT | $25 | Dec 18 | 37 | $$70 | 1 | SWEEP |
2 options trades shown · 0% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About ARQT
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for ARQT. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Zone Setup — $ARQT (Arcutis Biotherapeutics, Inc.) Price: $26.58 | Zone: $23.10 — $26.75 Conviction: LOW | Analyst upside: +43.6% Near resistance (95% of range) — breakout watch. No recent news — te...
Join 3,500+ traders discussing ARQT in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Arcutis Biotherapeutics, Inc. (ARQT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (8 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →ARQT — frequently asked questions
What is ARQT stock price today?
Arcutis Biotherapeutics, Inc. (ARQT) is at $28.38, up 3.63% (+$0.99) at the Nov 11, 2026 close.
Why is ARQT stock moving today?
Latest ARQT news — Nov 5, 2026: TD Cowen keeps Buy rating on Arcutis Biotherapeutics, lifts target to $40 · Nov 5, 2026: Arcutis Biotherapeutics insider sells shares
Why did ARQT stock move on Nov 5, 2026?
Arcutis Biotherapeutics shares fell 6.90% on Tuesday, closing at $27.00 after trading between a low of $25.78 and a high of $29.49 on volume of about 7.5 million shares. The decline came despite several positive developments, including TD Cowen reiterating its Buy rating and raising its price target to $40, as well as the company starting a Phase 3 trial of ZORYVE Cream 0.3% and beginning enrollment in the INTEGUMENT-3 trial of ZORYVE for atopic dermatitis.
What is the ARQT price target?
The average analyst price target for ARQT is $40.00, ranging from $36 to $48, based on 7 analysts. Latest: TD Cowen maintains on Nov 5, 2026.
What do analysts rate ARQT?
Analyst ratings for ARQT: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
Did ARQT beat earnings?
ARQT last reported on Nov 4, 2026: EPS $0.06 vs $0.18 expected — a miss of 66.7%.
What is ARQT's P/E ratio?
ARQT trades at a P/E of 154.8 vs a Healthcare average of 18.5.
Does ARQT pay a dividend?
ARQT does not currently pay a dividend.
How much debt does ARQT have?
Arcutis Biotherapeutics, Inc. reported $109M of debt and $34M of cash (Jun 30, 2026).
What are ARQT support and resistance levels?
Support: $27.64, $25.23, $23.37. Resistance: $30.91, $34.80.
What are insiders doing with ARQT?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on ARQT?
Nov 5, 2026: TD Cowen keeps Buy rating on Arcutis Biotherapeutics, lifts target to $40 · Nov 5, 2026: Arcutis Biotherapeutics insider sells shares